Close menu
Brain & Behavior
Grants & Prizes
Home
Research
Illness
Addiction
Anxiety Disorders
Attention-Deficit Hyperactivity Disorder (ADHD)
Autism Spectrum Disorder (ASD)
Bipolar Disorder
Borderline Personality Disorder (BPD)
Depression
Eating Disorders
Mental Illness (General)
Obsessive-Compulsive Disorder (OCD)
Post-Traumatic Stress Disorder (PTSD)
Schizophrenia
Suicide Prevention
Other Brain-Related Illnesses
Category
Basic Research
New Technologies
Early Intervention/ Diagnostic Tools
Next Generation Therapies
Blog
Get Involved
Give
Donate Today
Make a Memorial/Tribute Gift
Create an Event/Memorial Page
Find an Event/Memorial Page
Make a Stock/Securities Gift/IRA Charitable Rollover Gift
Donate Cryptocurrency
Get Involved
Other Giving Opportunities
$1 Million Challenge Match
Planned Giving
Research Partners
Donor Advised Funds
Workplace Giving
Team Up for Research!
Sponsorship Opportunities
Watch
Healthy Minds TV
Meet the Scientist Webinars
Videos
Connect
Ask the Expert
Join Us
Home
Grants
Grant FAQs
BBRF Young Investigator Grants
BBRF Independent Investigator Grants
BBRF Distinguished Investigator Grants
Prizes & Awards
Klerman & Freedman Prizes
Outstanding Achievement Prizes
Lieber Prize for Schizophrenia Research
Maltz Prize for Schizophrenia Research
Colvin Prize for Mood Disorders Research
Ruane Prize for Child and Adolescent Psychiatric Research
Goldman-Rakic Prize for Cognitive Neuroscience Research
The Pardes Humanitarian Prize
Productive Lives Awards
Blog
About Us
Who We Are
Our Impact
FAQs
Media Center
News
Press Releases
Opinion Pieces
In the News
Multimedia Library
Media Kit
Events & Webinars
Team Up for Research! Events
Healthy Minds TV
Contact
Email Signup
Open Menu

Menu

antipsychotics

antipsychotics

Lumateperone, an Antipsychotic, is Tested in a Phase 3 Trial for Major Depressive Episodes in Bipolar I and II Disorders
Lumateperone, an Antipsychotic, is Tested in a Phase 3 Trial for Major Depressive Episodes in Bipolar I and II Disorders
An international team of researchers has reported positive results in a phase 3 clinical trial of a drug to treat... Read More
Study Links Schizophrenia Medicines’ Anticholinergic Impact to Risk of Cognitive Impairment
Study Links Schizophrenia Medicines’ Anticholinergic Impact to Risk of Cognitive Impairment
An important study led by BBRF grantees has closely examined a commonplace pharmacologic property of many antipsychotic and other medications... Read More
Combining the Antipsychotic Olanzapine with an Opioid-Receptor Blocker Significantly Limited Weight-Gain Risk in Schizophrenia Patients
Combining the Antipsychotic Olanzapine with an Opioid-Receptor Blocker Significantly Limited Weight-Gain Risk in Schizophrenia Patients
A clinical trial involving over 500 adults diagnosed with schizophrenia has found that by adding the drug samidorphan to the... Read More
Drugs Targeting the Glutamate System Warrant Continued Development for Schizophrenia, Study Finds
Drugs Targeting the Glutamate System Warrant Continued Development for Schizophrenia, Study Finds
In the continuing effort to develop new medicines to treat schizophrenia , a team led by BBRF Scientific Council member... Read More
Study Finds Changes in the Treatment of Bipolar Disorder Over 20 Years
Study Finds Changes in the Treatment of Bipolar Disorder Over 20 Years
A study covering the 20 years between 1997 and 2016 shows that substantial changes have occurred in the way doctors... Read More

TOPICS

Tags

Immune System
maternal health
Memory Loss
Fear
Genetics
25 Years of Breakthroughs
Alcohol Addiction
Mental Illness (General)
Epigenetics
Drug Addiction
Fragile X Syndrome
antidepressants
neurotransmitters
Plasticity/Neuroplasticity
Developmental Disorders
exercise & mental health
Biomarkers
Stress
ketamine
side effects
Trauma
SSRI
Psychosis
CBT
Gender Differences
suicide
Copy-Number Variations
antipsychotics
cognitive deficits
Children & Adolescents
Intellectual Disability
DBS
Brain Stimulation
Alzheimer's Disease
Geriatric Mental Health
Anorexia Nervosa
lithium
ECT
anhedonia
Prevention
neuroticism
Bulimia
schizoaffective
1997
panic disorder
Spain
Metabolic Syndrome
Neurodegenerative Disorders
Cognition
Addiction
Infection & Mental illness
Metabolism
video
serotonin
White Matter/Grey Matter
sleep
Parkinson's Disease
Dietary Supplements
Folic Acid
pregnancy
choline
Blog
Dopamine
Tourette syndrome
tic disorder
brain circuits
NARSAD Artworks
borderline personality disorder
Diet
Neurofeedback
Cognitive Impairment
Substance Abuse
hippocampus
Postpartum Depression
Talk Therapy
Transcranial Magnetic Stimulation (TMS)
Brain Imaging
DTI
Basal Ganglia
Lateral Habenula
Rett Syndrome
rapid-acting antidepressants
bipolar depression
suicide prevention
suicidal thinking
brain waves
electrical stimulation
disruptive mood dysregulation disorder
Mood Disorders
mental-illness multiple
prefrontal cortex
epilepsy
inhibitory neurons
synapses
Amygdala
Resilience
imaging
memory
Baclofen
mania
excitation/inhibition balance
neural networks
Microbiome
light therapy
Marijuana
Autism
behavioral therapy
cognitive behavioral therapy
brain mapping
cell biology
neurons
mu receptor
opioids
Fear Memory
early life trauma
Aging
longitudinal studies
major depressive disorder
recovery
electroconvulsive therapy
treatment-resistant depression
vagus nerve stimulation
VNS
fast-acting antidepressants
veterans
Metabolic Disorders
Cocaine
reward system
Neuroimaging
birth complications
Psychotherapy
suicide risk
Cannabis
THC
Cognitive Dysfunction
Myelination
Negative Symptoms
Motivation
Brain & Behavior Magazine September 2018
cognitive symptoms
brain development
Brain & Behavior Magazine March 2018
Brain & Behavior Magazine July 2017
ASD
cognitive remediation
schizotypal personality disorder
hypomania
blood-brain barrier
organoids
stem cells
perinatal period
cognitive training
individualized treatments
bright-light therapy
social anxiety
glutamate
Inflammation
Genome
Big Data
eye-tracking
brain scans
mood stabilizers
tDCS
PET
EEG
Impulse Control
Alcohol Use Disorder
placebo effect
Screen Time
Electronic Media Use
oxytocin
insomnia
sleep disorders
loneliness
CRISPR
cognitive decline
cognitive function
treatment response
MST
COVID-19
exposure therapy
pandemic
mitochondria
excitatory neurons
iTBS
brainwaves
aripiprazole
GWAS
PMDD
menstrual cycle
vitamin d
fetal brain development
Obesity
Parenting
rumination
mindfulness
phone-based apps
brain fog
dementia
SAINT
SNT
NMDA receptor
oxygen therapy
Sensorimotor
fMRI
biology of the brain
neuronal signaling
denate gyrus
prodrome
seizures
neurogenesis
astrocyte
acetylation
BRD4
beta-arrestin
G-protein
sleep apnea
mTOR
hypoxia
rapamycin
SRI
Metacognitive Training
MCT
self-esteem training
neurodevelopmental illness
PGC
SCHEMA
noninvasive stimulation
auditory cortex
social communication
social brain
multiple sclerosis
brain networks
magnet seizure therapy
brain aging
Positive Symptoms
machine learning
thalamus
gut bacteria
tobacco
striatum